{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:11:23Z","timestamp":1782515483116,"version":"3.54.5"},"reference-count":27,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:p> This multicentre, double-blind study was undertaken to demonstrate non-inferiority of once-daily oral moxifloxacin compared with combination therapy in the management of acute, uncomplicated pelvic inflammatory disease (PID). Women aged \u226518 years with PID were randomized to receive moxifloxacin (400 mg once daily) for 14 days or comparator treatment (doxycycline [100 mg twice daily] plus metronidazole [400 mg three times daily] for 14 days, plus one single 500-mg ciprofloxacin dose). Of the 434 valid per protocol (PP) patients, the overall clinical success rates at 2\u201314 days post-therapy were 96.6% (moxifloxacin) and 98.0% (comparator); moxifloxacin was non-inferior to the comparator regimen both in the PP (95% confidence interval [CI]: \u22124.5, 1.6) and intent-to-treat (95% CI: \u22125.8, 6.9) populations. Clinical success rates at 21\u201335 days post-therapy were 93.8% (166\/177; data missing for 47 patients) for moxifloxacin and 91.3% (147\/161; data missing for 37 patients) for the comparator. Bacteriological success rates at 2\u201314 days post-therapy were 92.5% (moxifloxacin) and 88.2% (comparator). Once-daily dosing and proven efficacy suggest that moxifloxacin may be of value in acute, uncomplicated PID. <\/jats:p>","DOI":"10.1258\/ijsa.2008.008495","type":"journal-article","created":{"date-parts":[[2009,10,8]],"date-time":"2009-10-08T23:49:28Z","timestamp":1255045768000},"page":"690-695","source":"Crossref","is-referenced-by-count":28,"title":["A randomized double-blind comparison of moxifloxacin and doxycycline\/metronidazole\/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease"],"prefix":"10.1177","volume":"20","author":[{"given":"M","family":"Heystek","sequence":"first","affiliation":[{"name":"Department of Family Medicine, University of Pretoria, Pretoria, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J D C","family":"Ross","sequence":"additional","affiliation":[{"name":"Whittall Street Clinic, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2009,10,1]]},"reference":[{"key":"bibr-IJSA-08-495C1","doi-asserted-by":"publisher","DOI":"10.1258\/095646207782193911"},{"key":"bibr-IJSA-08-495C2","unstructured":"Royal College of Obstetricians and Gynaecologists. Management of Acute Pelvic Inflammatory Disease. 2003; RCOG Guideline No. 32: 9pp"},{"key":"bibr-IJSA-08-495C3","first-page":"56","volume":"55","author":"Centers for Disease Control and Prevention","year":"2006","journal-title":"MMWR"},{"key":"bibr-IJSA-08-495C4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1995.tb11294.x"},{"key":"bibr-IJSA-08-495C5","doi-asserted-by":"publisher","DOI":"10.1177\/147323000303100108"},{"key":"bibr-IJSA-08-495C6","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(94)70094-X"},{"key":"bibr-IJSA-08-495C7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1987.tb03125.x"},{"key":"bibr-IJSA-08-495C8","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-199207000-00001"},{"key":"bibr-IJSA-08-495C9","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e3282f3d9ac"},{"key":"bibr-IJSA-08-495C10","unstructured":"CDC. Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. JAMA 2007;297:2466\u20138"},{"key":"bibr-IJSA-08-495C11","first-page":"79","volume":"47","author":"Centers for Disease Control and Prevention: pelvic inflammatory disease","year":"1998","journal-title":"MMWR"},{"key":"bibr-IJSA-08-495C12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.1.101"},{"key":"bibr-IJSA-08-495C13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.3.709"},{"key":"bibr-IJSA-08-495C14","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.6.825"},{"key":"bibr-IJSA-08-495C15","first-page":"113","volume":"61","author":"Hager WD","year":"1983","journal-title":"Obstet Gynecol"},{"key":"bibr-IJSA-08-495C16","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(80)90592-X"},{"key":"bibr-IJSA-08-495C17","unstructured":"HemsellDL, SolomokinJS, SweetRL, TallyF, BartlettJG, CarbonC. General Guidelines for the Evaluation of Pelvic Inflammatory Disease in Hospitalized Women. BeamTR, GilbertDN, KuninCM, eds. European Society of Chemotherapy and Infectious Diseases. 1993:70\u201380"},{"key":"bibr-IJSA-08-495C18","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-199306000-00002"},{"key":"bibr-IJSA-08-495C19","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(91)91479-G"},{"key":"bibr-IJSA-08-495C20","doi-asserted-by":"publisher","DOI":"10.1155\/S1064744999000228"},{"key":"bibr-IJSA-08-495C21","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2005.019109"},{"key":"bibr-IJSA-08-495C22","first-page":"27","volume-title":"Moxifloxacin in Practice","volume":"1","author":"Felmingham D","year":"1999"},{"key":"bibr-IJSA-08-495C23","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.suppl_2.1"},{"key":"bibr-IJSA-08-495C24","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2002.121625"},{"key":"bibr-IJSA-08-495C25","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.6.2416-2418.2000"},{"key":"bibr-IJSA-08-495C26","volume-title":"The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) Year 2007 Report","author":"GRASP Steering Group","year":"2007"},{"key":"bibr-IJSA-08-495C27","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use Document reference EMEA\/CHMP\/524251\/2008. Available at: http:\/\/www.emea.europa.eu\/pdfs\/human\/referral\/avelox\/moxifloxacin_avelox_bi_en.pdf (last checked November 2008)"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1258\/ijsa.2008.008495","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1258\/ijsa.2008.008495","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1258\/ijsa.2008.008495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T08:24:05Z","timestamp":1740990245000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1258\/ijsa.2008.008495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1258\/ijsa.2008.008495"],"URL":"https:\/\/doi.org\/10.1258\/ijsa.2008.008495","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}